Arpeggio Biosciences, a Boulder, CO-based preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, raised $17m in Series A funding.
The round, which follows a $3.2m seed round completed in 2020, was led by Builders VC with participation from Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, and Fifty Years, with new participation from Tencent, ATEM Capital, Formic Ventures, Tau Ventures, Milad Alucozai (BoxOne Ventures), and Matthew De Silva (Longtail Capital).
The company intends to use the funds to advance its drug pipeline as well as its transcription-monitoring technologies.
Co-founded by Chief Executive Officer Joey Azofeifa, Chief Technology Officer Tim Read, and Chief Operating Officer Laura Norris, Arpeggio provides a proprietary platform with a database of nascent-RNA sequences. The technology combines a proprietary biological assay and machine learning algorithms that, together, enable rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots are then analyzed to reveal the biological networks that determine a drug’s function and guide therapeutic development. Arpeggio’s technology reads out on transcription directly and can monitor the activity of more than 100,000 transcripts across diseased and healthy cells exposed to diverse stimuli such as small molecules, biologics, or ASOs. Using machine learning, the system reconstructs the biological networks affected by the molecule and matches the molecule to diseases where the compound could be therapeutically relevant.
FinSMEs
07/09/2022